Archives — Current Month (4)
An H.C. Wainwright & Co. report reviewed the arrangement.
With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system.
A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts.
A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate.
|"FDA approval of Perseris triggers a $5M milestone payment to DRRX."|